INCY - Incyte Corporation Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

INCY

INCYTE CORPORATION

NASDAQ

$124.37

▼ DOWN 2.64% (-3.37)

KEY STATISTICS

Market Cap$25.21 B

52w High$132.60

52w Low$81.09

Dividend Yield—

Frequency—

P/E16.72

Volume1.22M

Shares Out.202.70M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

William J. Meury

COMPENSATION 2026

Salary$1,392,499

Stock Awards$1,971,975

Incentive Plan Pay$1,026,072

All Other Comp.$295,945

Total$6,380,525

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 4, 1993

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

2,844

PRICE TARGET

Target High$155.00

Target Low$104.00

Target Median$130.00

Target Consensus$130.07

UPCOMING EARNINGS

DateOct 27, 2026

DayTuesday

Rev. Est.$1.47B

OCT

TUE

SPLIT RECORD

DATE	TYPE	RATIO
2000-09-01	Forward	2:1
1997-11-10	Forward	2:1

PRICE

$124.37 ▼ DOWN 2.64% (−$3.37)

OVERLAYS

About Incyte Corporation

https://www.incyte.com ↗

Incyte Corporation is a biopharmaceutical company developing proprietary therapies like Jakafi, Pemazyre, and Iclusig, with a diverse pipeline and collaborations targeting various cancers and immune disorders globally.

INDUSTRY

Biotechnology

A PRODUCT INCYTE CORPORATION IS KNOWN FOR

Opzelura (ruxolitinib) cream

Opzelura is the first FDA-approved topical JAK inhibitor by Incyte, treating vitiligo and atopic dermatitis, driving strong sales growth and expanding dermatology market presence.

COMPETITORS

COMPETITOR

Revenue by Products

PRODUCT	Q3-2025	Q4-2025	Q1-2026	Q2-2026
J A K A F I	$916.72M	$958.47M ▲	$863.31M ▼	$940.85M ▲
OPZELURA	$187.97M	$207.28M ▲	$143.01M ▼	$449.74M ▲
M I N J U V I	$41.99M	$41.91M ▼	$49.23M ▲	$53.69M ▲
ZYNYZ	$22.67M	$31.75M ▲	$41.39M ▲	$49.95M ▲
Olumiant Royalty	$37.11M	$43.21M ▲	$36.41M ▼	$38.48M ▲
I C L U S I G	$37.58M	$34.22M ▼	$35.46M ▲	$34.39M ▼
PEMAZYRE Royalty Revenues	$22.74M	$23.35M ▲	$22.54M ▼	$23.42M ▲
Milestone And Contract Revenue	$45M	$100M ▲	$17M ▼	$11.2M ▼
Tabrecta Royalty Revenues	$6.51M	$7.14M ▲	$5.98M ▼	$6.69M ▲